Migraines & headaches decisions — 2025

The Board remands the claims for service connection for left knee, low back, migraine headaches, tinnitus, and right knee disabilities due to a lack of proper notification for examinations.

The Board denied the Veteran's appeal for a rating in excess of 30 percent for migraine headaches, as the evidence did not support a higher rating.

The Board remands the issues of entitlement to a disability rating in excess of 10 percent from April 25, 2013, to May 26, 2016, and in excess of 30 percent from May 26, 2016, to January 30, 2023, for the service-connected headaches.

The Board granted service connection for a headache disability and hypertension, finding that the evidence supports an etiological link to the Veteran's active duty service.

The Board denied the Veteran's claims for an allowance for an automobile or other conveyance and adaptive equipment, as well as a certificate of eligibility for specially adapted housing (SAH), due to the lack of evidence showing permanent loss of use of any extremities or hands.

The Board granted service connection for headaches secondary to the Veteran's service-connected depressive disorder.

The appeal for service connection for a cervical spine condition was dismissed due to an untimely Notice of Disagreement (VA Form 10182). The claims for an initial compensable rating for migraines and service connection for urinary incontinence were remanded for further development.

The Board granted an initial increased rating of 100 percent for depressive disorder with anxiety and a 50 percent rating for migraines, while denying increased ratings for rhinitis and sleep apnea. The appeal was dismissed for degenerative arthritis of the lumbar spine and right lower extremity radiculopathy.

The veteran withdrew all claims pending before the Board of Veterans' Appeals, and as such, the appeals for initial ratings and service connection were dismissed.

The veteran withdrew her appeal for service connection for various conditions, including right thumb deformity and pain, dental and oral numbness/tingling, lower back pain, a bilateral hip condition, left knee pain, right knee pain, polycystic ovarian syndrome, posttraumatic stress disorder, migraines, ringing in the ears, a spine disability, and sleep apnea.

The Veteran's migraines have been very frequent, completely prostrating, and involving prolonged attacks productive of severe economic inadaptability, warranting a 50 percent rating from December 9, 2022.

The Board remands the Veteran's claims for service connection for GERD and migraine headaches to the AOJ for correction of pre-decisional duty to assist errors.

The appeal of the service connection claim for left ear hearing loss was dismissed due to untimeliness. The remaining claims were remanded for further development.

The Board remands the claims for a back disorder, bilateral foot disorder, left ankle disorder, left eye disorder, and left hip disorder for further development of evidence.

The Board denied the veteran's claims for a compensable rating for right hip ligament strain with thigh impairment, a higher rating for right hip ligament strain with limitation of flexion, and service connection for migraines and GERD.

The Board granted service connection for an acquired psychiatric condition and headaches or migraines, but denied a compensable evaluation for bilateral hearing loss and service connection for PTSD and sleep apnea.

The Veteran's service-connected other headache syndrome was granted a 50 percent rating, effective March 13, 2022.

The Board granted an initial rating of 50 percent for tension headaches, resolving reasonable doubt in the Veteran's favor.

The Board granted an initial evaluation of 50 percent for service-connected cluster headaches, as the Veteran's symptoms more nearly approximate very frequent completely prostrating and prolonged attacks productive of severe economic inadaptability.

The Board granted earlier effective dates for service connection of lumbosacral strain, right knee strain (flexion and extension), and migraines, with an effective date of May 10, 2022.